Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Dermatologic 3CNS 3Lymphoid 2Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Melanoma 258Carcinoma, Non-Small-Cell Lung 226Carcinoma, Renal Cell 143Neoplasm Metastasis 97Neoplasms 93Carcinoma, Hepatocellular 85Squamous Cell Carcinoma of Head and Neck 84Colorectal Neoplasms 81Lung Neoplasms 73Stomach Neoplasms 56Pancreatic Neoplasms 56Carcinoma, Transitional Cell 49Hodgkin Disease 47Urinary Bladder Neoplasms 42Breast Neoplasms 40Ovarian Neoplasms 37Head and Neck Neoplasms 37Triple Negative Breast Neoplasms 34Small Cell Lung Carcinoma 33Sarcoma 32Prostatic Neoplasms 32Glioblastoma 32Brain Neoplasms 32Recurrence 27Kidney Neoplasms 27Multiple Myeloma 25Uveal Melanoma 23Esophageal Neoplasms 23Uterine Cervical Neoplasms 22Skin Neoplasms 22

Interventions

Vincristine 25Cyclophosphamide 25Irinotecan 21Temozolomide 18Doxorubicin 16Radiotherapy 15Filgrastim 15Ifosfamide 14Dactinomycin 14Etoposide 11Vinorelbine 9Melphalan 9Magnetic Resonance Spectroscopy 9Granulocyte Colony-Stimulating Factor 9Radiation 8pegfilgrastim 7X-Rays 7Specimen Handling 7Sirolimus 7Topotecan 6Phantoms, Imaging 6Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6cixutumumab 5Busulfan 5Biopsy 5temsirolimus 4irinotecan sucrosofate 4fludarabine 4etoposide phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Rhabdomyosarcoma × Nivolumab × Clear all
NCT05302921 2025-01-01

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Children's National Research Institute

Phase 2 Completed
5 enrolled
CNSDermatologicGastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Melanoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

National Cancer Institute (NCI)

Phase 1/2 Completed
140 enrolled 23 charts
CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT04730349 2023-03-24

PIVOT IO 020

Bristol-Myers Squibb

Phase 1/2 Terminated
15 enrolled 14 charts
CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡